Hydroxyzine Pamoate
- Product NDC
- 53002-6211
- 11-digit product format
- 530026211
- Labeler code
- 53002
- Product ID
- 53002-6211_0e79d89f-4422-4c5f-bfa1-fe83c9ac9855
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- Hydroxyzine Pamoate
- Dosage form
- CAPSULE
- Route
- ORAL
- Labeler
- RPK Pharmaceuticals, Inc.
- Application
- ANDA088496
- Marketing category
- ANDA
- Marketing start
- 1984-07-01
- Marketing end
- 0000-00-00
- Substance
- HYDROXYZINE PAMOATE
- Active strength
- 25 mg/1
- Pharmacologic classes
- Antihistamine [EPC],Histamine Receptor Antagonists [MoA]
- NDC exclude flag
- No
- Listing certified through
- 2021-12-31
- Current FDA listing
- Historical FDA.report record
DailyMed Product Concepts#
FDA-Initiated Inactive NDC Indexing#
DailyMed Package Descriptions#
Package NDC, Product, Description table| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|
| 53002-6211-1 | Hydroxyzine Pamoate | 10 in 1 BOTTLE | CAPSULE | 10 | | 3 |
| 53002-6211-2 | Hydroxyzine Pamoate | 20 in 1 BOTTLE | CAPSULE | 20 | | 3 |
| 53002-6211-3 | Hydroxyzine Pamoate | 30 in 1 BOTTLE | CAPSULE | 30 | | 3 |
DailyMed Dashboard NDC Coverage#
NDC, Dashboard title, SPL version table| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|
| 53002-6211 | HYDROXYZINE PAMOATE CAPSULE [RPK PHARMACEUTICALS, INC.] | 3 | Legacy NDC, 3 package rows | 20201218_362d0d0c-1977-4b19-ba62-228d910d69f9.zip |
DailyMed RxNorm Mappings#
Packages#
Package NDC, 11-digit format, Description table| Package NDC | 11-digit format | Description | Units | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|
| 53002-6211-1 | 53002621101 | 10 CAPSULE in 1 BOTTLE (53002-6211-1) | 10 capsule | 2018-10-01 | 0000-00-00 | No | No | Current |
| 53002-6211-2 | 53002621102 | 20 CAPSULE in 1 BOTTLE (53002-6211-2) | 20 capsule | 2018-10-01 | 0000-00-00 | No | No | Current |
| 53002-6211-3 | 53002621103 | 30 CAPSULE in 1 BOTTLE (53002-6211-3) | 30 capsule | 2018-10-01 | 0000-00-00 | No | No | Current |